Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Urological cancer. The benefits of intermittent androgen-deprivation therapy.

Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol. 2012 Dec; 9(12):672-3.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.